Effects of Different Doses of Quercetin on Apoptotic Markers and Liver Enzymes in Liver Injury Induced by Interferon Beta-1b (Betaferon) in Male Rats in Comparison with Silymarin
DOI:
https://doi.org/10.31351/vol34iss2pp108-115Keywords:
Drug induced liver injury, Interferon beta 1b(betaferon), Liver injury, Multiple sclerosis, Quercetin.Abstract
The first disease-modifying drug for the treatment of multiple sclerosis (MS) was interferon beta 1b (IFN).this drug demonstrated efficacy in relapse MS, But There are many difficulties in treating multiple sclerosis, including the well-known side effect of betaferon(hepatotoxicity or liver injury), which present as brief, mild elevations in serum aminotransferase (ALT,AST) levels appear 3 to 12 months after starting treatment. A naturally occurring antioxidant is quercetin which act as anti-oxidant, anti-inflammatory agent , it also have antiviral, anticancer and cardiovascular properties.The study aimed to investigate the apoptotic potential of betaferon on liver cells and to evaluate the hepatoprotective effect of the antioxidant quercetin , by downregulation of apoptotic biomarkers caspase 3 and caspase 9.The study was employed on 36 male rats for 17 days. rats were randomly divided into six groups (6 rats in each group) given daily doses given by Intraperitoneal route (i.p)as follow:Control group; (rats were administered distilled water),betaferon group or induction group ; (rats were administered Betaferon in a dose of 250 µ/kg for 16 days) ,treatment groups betaferon+ quercetin which divided into three subgroups according to the dose of quercetin (25,50,100mg/kg) ; (Rats were pretreated by a dose of 25,50,100mg/kg of quercetin suspension for 6 days then continue administering the same dose of quercetin plus betaferon 250µ/kg on day 7 for 10 days) .and the last group was Silymarin group; (rats were treated with 100 mg/kg of Silymarin suspension for 16 days).In the current study liver function enzymes such as alanine aminotransferase and aspartate aminotransferase also apoptotic markers which include caspase3 and caspase9 were measured.Betaferon significantly increased liver apoptotic markers caspase3 and caspase 9 also cause elevation in the liver enzymes(ALT,AST)compared to the control group. On the other side, quercetin significantly reduce these biomarkers(caspase 3,caspase 9)also restoring liver enzymes to its normal level. Quercetin showed antioxidant,anti_inflammatory and anti_apoptotic effects on the liver tissue of rats that were pretreated with querctin before receiving the betaferon,suggesting it has a beneficial effects on minimizing liver injury or hepatotoxicity caused by betaferon.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Filipi, Mary, and Samantha Jack. “Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update.” International journal of MS care, 2020; 22(4):165-172.
Bergamaschi, Roberto, et al. "Immunomodulatory therapies delay disease progression in multiple sclerosis." Multiple Sclerosis Journal 2016; 22(13): 1732-1740.
Hamdan, Sarah Saad, Yassir Mustafa Kamal, and Huda Jaber Waheed. "Astaxanthin effect on apoptotic biomarkers in methotrexate-induced liver injury." Al Mustansiriyah Journal of Pharmaceutical Sciences 2022; 22(3): 43-50.
John P. Cunha, DO, FACOEP.betaseron. Last updated on RxList: 9/20/2022.
Hervás-García, J. V., et al. "Toxic hepatitis after concomitant interferon beta and aloe vera treatment in a patient with multiple sclerosis: A case report." Neurologia (Barcelona, Spain) 2016; 32(8): 546-547.
Saeedi M, Forughipour M, Sasannezhad P, Shoeibi A. Interferon-Beta-1b Induced Autoimmune Hemolytic Anemia in a Patient with MS: A Case Report. Iran Red Crescent Med J. 2011;13(3):210-2.
Alanoglu, G., et al. "Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis." Multiple Sclerosis Journal .2007; 13(5): 683-685.
Lindhardt, Thomas Beck et al. “Male and Female C57BL/6 Mice Respond Differently to Awake Magnetic Resonance Imaging Habituation.” Frontiers in neuroscience. 2022; vol. 16 853527.
Guy, Jennifer, and Marion G Peters. “Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.” Gastroenterology & hepatology. 2013; 9(10) : 633-9.
Chen X. Protective effects of quercetin on liver injury induced by ethanol. Pharmacogn Mag. 2010; 6(22):135-41.
Zhang, Yueming, et al. "Quercetin attenuates NLRP3 inflammasome activation and apoptosis to protect INH-induced liver injury via regulating SIRT1 pathway." International Immunopharmacology (2020);106634: 85.
Bhatiya, Meenu et al. “A Comprehensive Study on the Anti-cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation.” Archivum immunologiae et therapiae experimentalis. 2023; 71(16).
Nair A., Jacob S. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 2016; 7(2): 27.
Rafiee Zadeh, Aryan et al. “Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.” International journal of physiology, pathophysiology and pharmacology, 2019; 11(4): 95-104.
Mukhtar, Shanza et al. “Hepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats.” Saudi journal of biological sciences. 2021; 28(1): 717-723.
Mengesha, T., Gnanasekaran, N. & Mehare, T. Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats. BMC Complement Med Ther. 2021; 21: 104.
Mahli, A., Koch, A., Czech, B. et al. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats. Clin Phytosci.2015; 1; 5.
Tsukamoto A, Niino N, Sakamoto M, Ohtani R, Inomata T. The validity of anesthetic protocols for the surgical procedure of castration in rats. Exp Anim. 2018; 30;67(3):329-336.
Aldrich S. Aspartate Aminotransferase (AST) Activity Assay Kit. 2017;1– 4.
Aldrich S. Alanine Aminotransferase (ALT)Activity Assay Kit. 2017;1–4.
Mybiosource. Rat Caspase-3 ELISA Kit. 2021;36(2):3–6.
Mybiosource. Rat Caspase-9 ELISA Kit. 2021;36(2):3–6.
Hamdan, Sarah Saad, Yassir Mustafa Kamal, and Huda Jaber Waheed. "Astaxanthin effect on apoptotic biomarkers in methotrexate-induced liver injury." Al Mustansiriyah Journal of Pharmaceutical Sciences.2022; 22(3): 43-50.
Azzam A, Jiyad Z, O’Beirne J. Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta-analysis. Australas J Dermatol. 2021;62(2):130–40.
Moriles KE, Azer SA. Alanine Amino Transferase. StatPearls.2020;(July).
Ebrahimi R, Sepand MR, Seyednejad SA, Omidi A, Akbariani M, Gholami M, et al. Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the IĸBα/NFĸB in rats. DARU, J Pharm Sci. 2019;27(2):721–33.
Jakimovski, Dejan, et al. "Interferon β for multiple sclerosis." Cold Spring Harbor perspectives in medicine. 2018; 8(11).
Durelli, Luca, et al. "Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS." Neurology2001;57(8): 1363-1370.
Noroozi, Saam, et al. "The effect of IFN-β 1a on biochemical factors in multiple sclerosis patients." Iran Red Crescent Med J 2017; 19(8).
Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008; 47(4):1363–70.
Kim J, Kim Y, Choi J, Jung H, Lee K, Kang J, et al. Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepaytes from patients with rheumatoid arthritis. Stem Cell Res Ther.2018; 9(1):1–15.
Abd Eldaim, Mabrouk Attia, et al. "Antioxidant and anti-apoptotic prophylactic effect of silymarin against lead-induced hepatorenal toxicity in rats. " Environmental Science and Pollution Research 28.41 (2021); 57997-58006.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences

This work is licensed under a Creative Commons Attribution 4.0 International License.